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pathophysiological basis of KOA is multifaceted and includes impaired
muscle function, reduced proprioceptive acuity, and the psychological
traits of chronic pain. Tai Chi is an ancient Chinese exercise that uses
an integrated mind-body approach to enhance muscle function, balance,
ﬂexibility, and reduce pain, depression and anxiety. Tai Chi may thus be
especially suited to the therapy of KOA.
Methods: We used a random number list to randomize 40 eligible indi-
viduals (age >55 yr, BMI 40 kg/m2 with knee pain on most days of the
previous month and tibiofemoral OA K/L grade 2) to Tai Chi (10 modiﬁed
forms from classical Yang style) or an attention control (stretching and
wellness education). The 60-minute intervention sessions occurred twice-
weekly for 12 weeks. The primary endpoint was change in the WOMAC
pain score (VAS) at 12 weeks. Secondary endpoints included WOMAC
function, patient and physician global assessments (VAS), timed chair
stand, balance tests, knee proprioception (Biometrics electrogoniometer),
depression (CES-D index), self-efﬁcacy, and health-related quality of life
(SF-36). We repeated these assessments at 24 and 48 weeks to test
durability of response. The Tai Chi and control groups were compared by
intention-to-treat using t-tests.
Table. Changes in primary and secondary outcomes
Variables Groups* Baseline At 12 week
Change
(95%CI)
P-Value
for D
between
group***
WOMAC-Pain VAS, 0–500mm Tai Chi 209.3
(58.5)
−157.3
(−198.5, −116)
0.0004
Control 220.4
(101)
−38.5
(−87.2, 10.3)
WOMAC-Physical function VAS, 0–1700mm Tai Chi 707.6
(246.9)
−506.8
(−635.5, −378)
0.001
Control 827.0
(258.8)
−182.2
(−321.8, −42.5)
Patient Global VAS, 1−10 cm Tai Chi 4.2
(2.1)
−3.0
(−3.9, −2.0)
0.003
Control 4.8
(2.0)
−0.8
(−1.9, 0.2)
Physician Global VAS, 1−10 cm Tai Chi 4.8
(1.7)
−3.1
(−3.9, −2.4)
0.0009
Control 5.8
(2.2)
−1.4
(−2.1, −0.8)
Chair stand test (sec) Tai Chi 40.8
(13.4)
−12.0
(−16.7, −7.4)
0.0005
Control** 35.6
(9.2)
−0.9
(−4.8, 3.0)
Proprioception (30 degree) Tai Chi 5.6
(4.2)
−2.5
(−5.0, −0.01)
0.01
Control** 4.3
(2.9)
2.1
(−0.6, 4.8)
Self efﬁcacy (0−25) Tai Chi 3.1
(1.1)
0.6
(−0.01, 1.2)
0.05
Control 3.3
(0.9)
−0.1
(−0.5, 0.3)
SF-36: PCS (0−50) Tai Chi 37.5
(8.5)
11.6
(7.6, 15.5)
0.005
Control 32.0
(8.8)
4.1
(0.7, 7.5)
SF-36: MCS (0−50) Tai Chi 51.4
(12.2)
2.1
(−4.0, 8.3)
1.0
Control 50.8
(12.6)
1.9
(−2.6, 6.5)
CES-D (0−60) Tai Chi 13.6
(11.7)
−7.4
(−11.4, −3.4)
0.009
Control 9.3
(9.2)
−0.7
(−3.9, 2.5)
*N=20 for each group. **N=19. ***Signiﬁcant improvement of Tai Chi versus attention control at
week 12. CES-D = the Center for Epidemiology Studies Depression index, SF-36 (PCS) = Short-
Form health survey (physical component summary), SF-36 (MCS) = Short-Form health survey
(mental component summary), VAS = Visual Analogue Scale.
Results: The participants had mean age 65 y (SD 7.8), mean disease
duration 10 y (SD 7.6), mean BMI 30.0 kg/m2 (SD 4.8), and median K/L
grade 4; 75% were female, 70% were white. There were no signiﬁcant
differences at baseline in demographics, radiographic score, and out-
come measures. Participants’ baseline expectations of beneﬁt from an
exercise intervention were also similar between the two groups [outcome
expectations for exercise score for Tai Chi = 4.1 (SD 0.6), controls = 4.3
(SD 0.4)]. Attendance for the 12-week assessment was 85% in the Tai
Chi group and 89% in the attention control. Participants in the Tai Chi arm
exhibited signiﬁcantly greater improvements in pain, physical function, de-
pression, self-efﬁcacy and health status (Table). Patients who continued
Tai Chi practice after 12 weeks reported durable beneﬁts in WOMAC pain
[between-group difference −150.2 (SD 116.6), p=0.04 at week 24 and
−185.3 (SD 54.1), p=0.001 at week 48] and WOMAC function [between-
group difference −572.7 (SD 257.8), p=0.02 at week 48].
Conclusions: Tai Chi is efﬁcacious for treatment of pain and physical
impairment in people with severe KOA. Further studies should be per-
formed to replicate these results and deepen our understanding of this
therapeutic modality.
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Purpose: To assess the prevalence of osteoarthritis and medication
use among participants in a population-based cohort study conducted
in Australia.
Methods: The North West Adelaide Health Study is a representative
longitudinal cohort study of people aged 18 years and over living in
the northwest region of Adelaide, South Australia, Australia. The original
sample (n = 4060) was randomly selected and recruited by telephone
interview to participate in a clinic assessment. The second stage of
data collection from this cohort was undertaken between mid 2004 and
early 2006 and in this phase, information regarding the prevalence of
musculoskeletal conditions was included. The self reported prevalence
of arthritis (including osteoarthritis) was collected using a Computer As-
sisted Telephone Interview (CATI) survey. All medications that participants
were taking, including complementary and alternative medicines, were
recorded at the clinic visit.
Results: Overall, n = 3502 participants responded to the CATI component
of the study, with 7.5% (95% CI 6.6−8.4) reporting that they had been told
by a doctor that they had osteoarthritis. There was also 10.8% (95% CI
9.8−11.8) of respondents who reported that they did not know the type
of arthritis that they had. Among respondents who stated that they had
osteoarthritis, 22.3% (95% CI 17.4−28.1) were on COX-2 inhibitors and
11.0% (95% CI 7.6−15.6) were on a non steroidal anti-inﬂammatory
medication (NSAID, excluding aspirin). There were also 20.6% (95% CI
15.9−26.3) with osteoarthritis who reported that they took aspirin. Of the
respondents with osteoarthritis who took a non-selective NSAID there
were 11.2% who also took a COX-2 inhibitor and among the respondents
who took a non-selective NSAID (excluding aspirin) and/or a selective
NSAID (COX-2 inhibitor), a quarter (24.6%) also took aspirin, 7.4% took
alendronate and 3.2% took metformin. Of those with osteoarthritis and
taking any form of NSAID (excluding aspirin), 37.6% were also taking
proton pump inhibitors which might suggest gastroesophageal problems
and 37.9% had renal disease (using the Cockcroft-Gault equation to cal-
culate the glomerular ﬁltration rate (GFR), with renal disease deﬁned as
an estimated GFR of less than 60mL/min per 1.73m2). Respondents self-
reporting that they had osteoarthritis also took a variety of complementary
and alternative medicines. Overall, 13.7% (95% CI 9.9−18.8) took ﬁshoil
and 20.0% (95% CI 15.4−25.6) took glucosamine and/or chondroitin.
Conclusions: Medication is an important part of arthritis treatment and
fracture prevention, but even in those whose doctor had told them
they had arthritis, in particular osteoarthritis, opportunities to use anti-
inﬂammatory medications were missed or inappropriate medications were
used in conjunction with these drugs.
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Purpose: Osteoarthritis (OA) is characterized as a heterogeneous disor-
der with evidence of multigenic inheritance. Previous studies have identi-
ﬁed several candidate genes as well as novel loci on chromosomes 2, 7,
11 and 16 associated with OA at the hand, hip, knee and/or spine. The
goal of the Genetics of Generalized Osteoarthritis (GOGO) Study was
